Navigation Links
Imprimis Pharmaceuticals, Inc. to Present at the Southern California Investor Conference on Thursday, August 8, 2013 at the Island Hotel in Newport Beach, CA. The presentation is scheduled to begin at 11 a.m. ET / 8 a.m. PT
Date:8/5/2013

SAN DIEGO, Aug. 5, 2013 /PRNewswire/ -- Imprimis Pharmaceuticals, Inc. (NASDAQ: IMMY), which is focused on the commercialization of compounded drug formulations utilizing the FDA 505(b)(2) drug development pathway, today announced CEO Mark L. Baum will present at the Southern California Investor Conference on August 8, 2013 at the Island Hotel in Newport Beach, CA. The Imprimis presentation is scheduled to begin at 11 a.m. ET / 8 a.m. PT. in Room 2.

About Imprimis Pharmaceuticals, Inc.

Imprimis Pharmaceuticals, Inc. (NASDAQ: IMMY) is a specialty pharmaceutical company focused on the commercial development of drug formulations utilizing the FDA 505(b)(2) drug development pathway. Through its exclusive strategic relationship with the largest compounding pharmacy organization in North America as well as through a growing network of commercial development relationships with pharmacists and physicians across the United States, Imprimis expects to use proprietary drug delivery technologies, proven drug formulations and proprietary market data to identify and pursue pharmaceutical development opportunities where there is a significant unmet medical need.  Imprimis' most near term drug candidate, Impracor, is a Phase III product candidate that utilizes its patented Accudel topical cream formulation to deliver the active drug ketoprofen, a non-steroidal anti-inflammatory drug (NSAID), through the skin directly into the underlying tissues where the drug exerts its localized anti-inflammatory and analgesic effects. For more information, visit http://imprimispharma.com/

Contact: Josh Berg
Imprimis Pharmaceuticals, Inc.
(858) 704 4041


'/>"/>
SOURCE Imprimis Pharmaceuticals, Inc.
Copyright©2012 PR Newswire.
All rights reserved

Related medicine technology :

1. Imprimis Pharmaceuticals, Inc. Receives Institutional Review Board (IRB) Approval for its Phase III Clinical Trial Protocol; Phase III Clinical Trial to Begin in 3Q 2013
2. Imprimis Pharmaceuticals, Inc. Acquires Intellectual Property Assets from Buderer Drug Company
3. Imprimis Pharmaceuticals, Inc. to Present at the National Investment Banking Association (NIBA) Conference June 18th in New York City
4. Imprimis Pharmaceuticals Announces Underwriter Exercise of Over-Allotment Option
5. Imprimis Pharmaceuticals Out Licenses Its Proprietary IP to resolutionMD for Cosmeceutical Products
6. Imprimis Announces Key Leadership Appointments
7. Imprimis Announces Successful Results from its Pharmacokinetic Study for its Impracor Topical NSAID
8. Imprimis Pharmaceuticals Announces Pricing of Public Offering of 1,840,000 Shares of Common Stock
9. Imprimis to Begin New Study of Its Topical Analgesic Drug
10. Imprimis Names Two Experts To Its Science And Regulatory Board
11. Imprimis Pharmaceuticals Signs Agreement With DPT Labs For Clinical Supplies In Advance Of Planned Phase 3 Studies For Its Ketoprofen-Based Topical Anti-Inflammatory Drug
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:7/12/2017)... July 12, 2017  Eli Lilly and Company (NYSE: ... generic companies to resolve pending patent litigation in the U.S. ... regarding the Cialis ® (tadalafil) unit dose ... 26, 2020. As part of the agreement, Cialis exclusivity is ... 2018. "The unit dose patent for Cialis is ...
(Date:7/11/2017)... , July 11, 2017  Sysmex America, ... urinalysis diagnostic testing equipment as well as middleware ... a way to make quality assurance easier and ... "Sysmex is well known for the innovation that ... Quality Monitor elevates quality assurance processes to a ...
(Date:7/10/2017)... -- The Institute for In Vitro Sciences (IIVS), a ... a VITROCELL® inhalation exposure system thanks to a generous ... which is designed to replace animals in inhalation testing, ... airborne test materials in an environment that mimics the ... testing combustible tobacco products, as well as next generation ...
Breaking Medicine Technology:
(Date:7/26/2017)... ... ... An inventor from Salisbury, N.C., knows the difficulties involved with leech therapy. "I ... to keep leeches in place during therapy," she said. "That’s why I came up ... to keep a leech in place on the skin during therapy. It prevents the ...
(Date:7/26/2017)... ... July 26, 2017 , ... Written By: Ashley D. Beall, ... in drug therapy for patients living with relapsing and primary multiple sclerosis that ... cell targeted therapy that has been proven to significantly reduce signs of disease ...
(Date:7/26/2017)... ... July 26, 2017 , ... Evergreen Healthcare ... of their continued efforts to provide innovative offerings to their healthcare partners. These ... and build dynamic, high-performing teams to address healthcare IT’s biggest challenges. , “Adding ...
(Date:7/26/2017)... ... July 26, 2017 , ... It may be hard to ... accessible to people in the third world. Diseases that many developed countries consider rare ... who don't have access to vaccines. , On an upcoming segment of "Success Files", ...
(Date:7/26/2017)... ... July 26, 2017 , ... ... 2017 Process Validation and Process Validation Statistics Conferences in Bethesda, Maryland, 12 ... lifecycle challenges faced by process validation professionals and statisticians today. , “These ...
Breaking Medicine News(10 mins):